Oncogenic mutations and amplifications in ERBB2 are detected by next-generation sequencing in 2%-4% of patients with NSCLC and are associated with constitutive HER2 activation.
Learn more about HER2 mutations in NSCLC.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: ERBB2 (HER2) Mutation in Non-Small Cell Lung Cancer - Medscape - Nov 23, 2021.
Comments